Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma Academic Article uri icon

Overview

MeSH Major

  • Germ-Line Mutation
  • Lung Neoplasms
  • Mesothelioma
  • Pleural Neoplasms
  • Tumor Suppressor Proteins
  • Ubiquitin Thiolesterase

abstract

  • Trimodality therapy including adjuvant hemithoracic IMPRINT, chemotherapy, and P/D is associated with promising OS rates and decreased toxicity in patients with MPM. Dose constraints should be applied vigilantly to minimize serious adverse events.

publication date

  • October 21, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5499250

Digital Object Identifier (DOI)

  • 10.1016/j.jtho.2017.02.026

PubMed ID

  • 28341225

Additional Document Info

start page

  • 993

end page

  • 1000